Master Cardiology
for MRCP Part 1

What the MRCP Part 1 Tests in Cardiology

MRCP Part 1 Cardiology tests the ability to interpret clinical presentations, ECG findings, and echocardiographic data to diagnose and manage common and important cardiovascular conditions. Candidates must demonstrate knowledge of ischaemic heart disease (including NSTEMI/STEMI management, GRACE score, and dual antiplatelet therapy), heart failure (with preserved vs reduced ejection fraction, guideline-directed medical therapy including sacubitril/valsartan and SGLT2 inhibitors), valvular disease (aortic stenosis severity criteria, timing of intervention), arrhythmias (AF management with CHA2DS2-VASc and HAS-BLED, narrow vs wide complex tachycardia algorithms), hypertension (NICE/ESC thresholds, resistant hypertension workup), and cardiomyopathies (HOCM, dilated, restrictive). Aortic dissection (Stanford classification), pericarditis, infective endocarditis (Duke criteria), and adult congenital heart disease (ASD, VSD, coarctation) are also tested. Questions often require applying guideline cut-offs (e.g., LVEF <40%, aortic valve area <1.0 cm²) and recognising drug side effects (e.g., amiodarone, beta-blockers).

High-Yield Concepts

• NSTEMI/STEMI Management: For STEMI, primary PCI within 120 minutes of diagnosis; if >120 minutes, give fibrinolysis (tenecteplase). For NSTEMI, use GRACE score: >140 high risk, consider early invasive strategy (<24h). Dual antiplatelet therapy: aspirin plus ticagrelor (or prasugrel) for 12 months. Contraindications to fibrinolysis include previous haemorrhagic stroke, active bleeding, recent surgery.
• Heart Failure with Reduced Ejection Fraction (HFrEF): First-line: ACE inhibitor (e.g., ramipril) or ARNI (sacubitril/valsartan if still symptomatic on ACEi), beta-blocker (bisoprolol, carvedilol, nebivolol), MRA (spironolactone, eplerenone). Add SGLT2 inhibitor (dapagliflozin, empagliflozin) regardless of diabetes. LVEF <40% defines HFrEF. For decompensated HF, give IV furosemide; if cardiogenic shock, consider inotropes (dobutamine) or LVAD.
• Aortic Stenosis Severity: Severe AS defined by: aortic valve area <1.0 cm², mean gradient >40 mmHg, peak jet velocity >4.0 m/s. Symptoms (angina, syncope, dyspnoea) trigger valve replacement (SAVR or TAVI). Asymptomatic severe AS with LVEF <50% also warrants intervention. Dobutamine stress echo can distinguish true severe vs pseudo-severe AS in low-flow, low-gradient cases.
• Atrial Fibrillation Stroke Prevention: CHA2DS2-VASc score: congestive HF (1), hypertension (1), age ≥75 (2), diabetes (1), stroke/TIA (2), vascular disease (1), age 65-74 (1), female sex (1). Score ≥2 in men, ≥3 in women: start anticoagulation (DOAC preferred: apixaban, rivaroxaban, edoxaban, dabigatran). HAS-BLED score >3 indicates high bleeding risk but is not a contraindication to anticoagulation.
• Infective Endocarditis Duke Criteria: Major: positive blood culture (typical organism from 2 separate sets), echocardiographic evidence (vegetation, abscess, new partial dehiscence of prosthetic valve). Minor: predisposing condition, fever >38°C, vascular phenomena (e.g., septic emboli), immunological phenomena (e.g., Osler nodes, Roth spots), positive blood culture not meeting major. Definite: 2 major, or 1 major + 3 minor, or 5 minor. Empiric treatment: amoxicillin + gentamicin (native valve) or vancomycin + gentamicin (prosthetic valve).
• Aortic Dissection Classification and Management: Stanford type A (involving ascending aorta) requires emergency surgery. Type B (descending aorta only) managed medically with aggressive blood pressure control (target SBP 100-120 mmHg) using IV labetalol or esmolol, plus IV nitroprusside if needed. Malperfusion or rupture in type B may require TEVAR. Imaging: CT aortogram is first line; transoesophageal echo useful in unstable patients.
• Hypertension Thresholds and Resistant HTN: NICE: clinic BP ≥140/90 mmHg; ABPM daytime average ≥135/85 mmHg. Target: <140/90 (clinic) or <135/85 (ABPM) for most; <130/80 if CKD, diabetes, or CVD. Resistant hypertension: BP above target despite 3 agents (including a diuretic). Workup: check adherence, exclude secondary causes (renal artery stenosis, phaeochromocytoma, primary aldosteronism), consider spironolactone as fourth-line.
• Pericarditis Diagnosis and Treatment: Diagnosis: pleuritic chest pain relieved by leaning forward, pericardial rub, diffuse ST elevation on ECG (concave upward, PR depression), pericardial effusion. First-line: NSAIDs (ibuprofen 600 mg TDS) plus colchicine 0.5 mg BD for 3 months. Avoid anticoagulation if large effusion. Corticosteroids reserved for refractory cases (e.g., autoimmune aetiology).

Common Traps in Cardiology Questions

• Confusing CHA2DS2-VASc with HAS-BLED: the former is for stroke risk, the latter for bleeding risk; a high HAS-BLED does not automatically preclude anticoagulation.
• Assuming all wide-complex tachycardias are VT: always consider SVT with aberrancy; use Brugada criteria or aVR lead algorithm.
• Forgetting that beta-blockers are contraindicated in acute decompensated HF with signs of congestion or hypotension; start only after euvolemia.
• Misinterpreting low-gradient aortic stenosis: a patient with LVEF <50% and aortic valve area <1.0 cm² but mean gradient <40 mmHg may have pseudo-severe AS; dobutamine stress echo is key.
• Using digoxin as first-line rate control in AF with HFrEF: beta-blockers are preferred; digoxin is second-line.
• Missing the diagnosis of pulmonary embolism in a patient with chest pain and tachycardia; always check D-dimer and consider CT pulmonary angiogram.

How to Revise Cardiology for the MRCP Part 1

Focus on guideline-based cut-offs and decision algorithms. For MRCP Part 1, prioritise memorising CHA2DS2-VASc and HAS-BLED scores, aortic stenosis severity parameters, and HFrEF drug sequence (ACEi/ARNI → beta-blocker → MRA → SGLT2i). Practise ECG interpretation of STEMI, pericarditis, and wide-complex tachycardia. Questions often present a scenario with a single abnormal value (e.g., LVEF 35%, aortic valve area 0.9 cm²) and ask for the next step. Revise Duke criteria for endocarditis and Stanford classification for dissection. Use NICE/ESC guidelines for hypertension thresholds and target organ damage. Review drug side-effect profiles (e.g., amiodarone causing thyroid dysfunction, pulmonary fibrosis; beta-blockers causing bradycardia, bronchospasm). Spend time on arrhythmia algorithms (e.g., narrow complex tachycardia: vagal manoeuvres → adenosine → verapamil).

Practise it: MedLumen has 50 Cardiology questions for the MRCP Part 1, each with a full explanation and references.